We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellectricon, Censo Biotechnologies Collaborate
News

Cellectricon, Censo Biotechnologies Collaborate

Cellectricon, Censo Biotechnologies Collaborate
News

Cellectricon, Censo Biotechnologies Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellectricon, Censo Biotechnologies Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellectricon AB has announced a commercial collaboration with Censo Biotechnologies Ltd. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research. “Through our collaboration with Censo, we are able to significantly enhance our discovery services offering for CNS and pain research”, said Cellectricon’s CEO David Burns.

“Censo’s extensive stem cell knowledge complements our current expertise and screening service offering in the field of neuroscience. This collaboration provides the opportunity to meet industry’s demands for drug discovery models that are closer, and therefore more relevant, to humans.

Censo’s CEO Aidan Courtney added: “Censo is committed to the use of ethically approved Human iPSCs and their derivatives to advance drug discovery. There is an excellent alignment between Censo and Cellectricon and we are very excited about this collaboration. With our extensive expertise, we can provide important stem cell knowledge that adds further value to Cellectricon’s proprietary discovery services”.

Advertisement